Ganciclovir-d5(Synonyms: BW 759-d5; 2′-Nor-2′-deoxyguanosine-d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Ganciclovir-d5 (Synonyms: BW 759-d5; 2′-Nor-2′-deoxyguanosine-d5)

Ganciclovir-d5 (BW 759-d5) 是 Ganciclovir 的氘代物。Ganciclovir (BW 759) 是一种核苷类似物和口服抗病毒药物，对 CMV 具有抗病毒活性。Ganciclovir 在体外对疱疹病毒 (herpes group) 和其他一些 DNA 病毒也具有抗病毒活性。Ganciclovir 抑制人类疱疹病毒 (HSV 1 型和 2 型，CMV) 和腺病毒血清型1、2、4、6、8、10、19、22 和 28 的体外复制。Ganciclovir 对猫 1 型疱疹病毒 (FHV-1) 的IC50为 5.2 μM。

Ganciclovir-d5(Synonyms: BW 759-d5; 2

Ganciclovir-d5 Chemical Structure

CAS No. : 1189966-73-1

规格 价格 是否有货
1 mg ￥3000 询问价格 & 货期
5 mg ￥13000 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Ganciclovir-d5 (BW 759-d5) is the deuterium labeled Ganciclovir. Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1)[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

260.26

Formula

C9H8D5N5O4
CAS 号

1189966-73-1
中文名称

更昔洛韦 d5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597-638.

    [3]. Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403.

    [4]. Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115.

    [5]. Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12.

    [6]. Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4.

    [7]. Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39(3):189-197.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务